Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dinah Sah, Bernard Ravina, David Rodman, Casi DeYoung

Premium

Voyager Therapeutics, a startup developing adeno-associated viral vector therapies, including RNAi-based ones, for central nervous system disorders, has named Dinah Sah as its senior vice president of neuroscience.

Sah was previously vice president of research at Alnylam Pharmaceuticals.

Voyager has also appointed Bernard Ravina to the position of vice president of clinical development. He most recently was medical director of clinical development at Biogen Idec.


MiRagen Therapeutics has named David Rodman as executive vice president of research and development.

Rodman was most recently vice president of clinical development at Vertex Pharmaceuticals.


Mirna Therapeutics said it has named Casi DeYoung as its chief business officer.

Previously, DeYoung was vice president of business development at ODC Therapy.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.